MIM
MYGN icon

Macroview Investment Management’s Myriad Genetics MYGN Stock Holding History

Macroview Investment Management’s Portfolio MYGN Stock Details MYGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-71
Closed -$1K – 368
2020
Q1 		$1K Hold
71
– – ﹤0.01% 291
2019
Q4 		$2K Hold
71
– – ﹤0.01% 277
2019
Q3 		$2K Hold
71
– – ﹤0.01% 266
2019
Q2 		$2K Hold
71
– – 0.01% 277
2019
Q1 		$2K Hold
71
– – 0.01% 297
2018
Q4 		$2K Hold
71
– – 0.01% 279
2018
Q3 		$3K Buy
+71
New +$3.16K 0.01% 241

Other funds holding MYGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
EARNEST Partners
EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
DGI
Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Macroview Investment Management's MYGN Position: Q2 2020 in Review

Macroview Investment Management sold out of Myriad Genetics (MYGN) in Q2 2020, closing a stake of 71 shares — an estimated $1K sold.

Macroview Investment Management first reported a position in MYGN in Q3 2018 and held it in 7 quarters. The position peaked at $3K in Q3 2018. 196 funds tracked by Wall St. Rank hold MYGN as of Q2 2020.

  • Macroview Investment Management reported no remaining Myriad Genetics position as of Q2 2020 after selling out during the quarter.
  • Macroview Investment Management sold 71 Myriad Genetics shares in Q2 2020, an estimated $1K.
  • Macroview Investment Management first reported a position in Myriad Genetics in Q3 2018 and held it in 7 quarters.
  • Macroview Investment Management's Myriad Genetics position peaked at $3K in Q3 2018.
  • 196 funds tracked by Wall St. Rank held Myriad Genetics as of Q2 2020.

Based on Macroview Investment Management's 13F filing for Q2 2020, filed 11 Aug 2020.